2Suppliers
11Customers
2Debt Items
0Related Chains

Source-Backed Evidence Depth

Estrella Immunopharma, Inc. (ESLA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships
2Distinct source URLs
4High confidence
0.696Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Estrella Immunopharma, Inc. Suppliers

TickerNameConfidenceEvidence
EUREKA EUREKA 92% On June 28, 2022, we entered into the License Agreement with Eureka and Eureka Therapeutics (Cayman), Inc. to license certain functions related to any T-cell products that incorporate (a) the ARTEMIS…
IMUGENE IMUGENE 90% On October 29, 2021, Eureka entered into a collaboration agreement (the “Collaboration Agreement”) with Imugene, a clinical stage immuno-oncology company, to evaluate the use of CF33-CD19t in conjunc…

Estrella Immunopharma, Inc. Customers

TickerNameConfidenceEvidence
CAYMAN-LTD CAYMAN-LTD 62% of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term. 12 The Company r…
COFAME-INVESTMENT-HOLDING-LLC COFAME-INVESTMENT-HOLDING-LLC 62% of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term. 12 The Company r…
CONTRIBUTION-AGREEMENT-EUREKA-THERAPEUTICS-INC CONTRIBUTION-AGREEMENT-EUREKA-THERAPEUTICS-INC 62% of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term. 12 The Company r…
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% Agreement Pursuant to the License Agreement with Eureka, we were obligated to make, and may be required to make as applicable: (i) a one-time, non-refundable, non-creditable payment of $1.0 million, …
ESTRELLA-BIOPHARMA-INC ESTRELLA-BIOPHARMA-INC 62% Warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.00001 per warrant share pursuant to its shelf registration statement. The Company also issued Common Stock Warrants ex…
HONG-KONG-CO-LTD HONG-KONG-CO-LTD 62% Warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.00001 per warrant share pursuant to its shelf registration statement. The Company also issued Common Stock Warrants ex…
LIANHE-WORLD-LIMITED LIANHE-WORLD-LIMITED 62% of interest that the Company would have to pay to borrow, on a collateralized basis, an amount equal to the lease payments, in a similar economic environment and over a similar term. 12 The Company r…
PLENTIFUL-LIMITED PLENTIFUL-LIMITED 62% s AA Preferred Stock that was issued and outstanding immediately prior to the Effective Time was automatically converted into a number of shares of Estrella Common Stock (See Note 12); ● Each share o…
TRADEUP-ACQUISITION-CORP TRADEUP-ACQUISITION-CORP 62% Warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.00001 per warrant share pursuant to its shelf registration statement. The Company also issued Common Stock Warrants ex…
UPTD-TRADEUP-ACQUISITION-SPONSOR-LLC UPTD-TRADEUP-ACQUISITION-SPONSOR-LLC 62% contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. License Agreement Pursuant to the License Agreement, we were obligated to make…
WHITE-LION-CAPITAL-LLC WHITE-LION-CAPITAL-LLC 62% Warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.00001 per warrant share pursuant to its shelf registration statement. The Company also issued Common Stock Warrants ex…

Estrella Immunopharma, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ESLA-DEBT-9359 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-06-30.
ESLA-DEBT Debt stack $6,000 90% Market cache reports total debt of $6,000.

Estrella Immunopharma, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Estrella Immunopharma, Inc..

Estrella Immunopharma, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Estrella Immunopharma, Inc..

Estrella Immunopharma, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.
🔐
ESLA
Unlock ESLA Supply Chain Data
Verified relationships include:
EUREKAEUREKASupplier92%
IMUGENEIMUGENESupplier90%
CAYMAN-LTDCAYMAN-LTDCustomer62%
COFAME-INVESTMENT-HOLDING-LLCCOFAME-INVESTMENT-HOLDING-LLCCustomer62%
+11 more relationships locked
Subscribe — View plans →